Kodiak Sciences Tech Stack

Retinal disease therapeutics with AI-enabled drug discovery platform

Biotechnology Research Palo Alto, California 51–200 employees Founded 2009 Public Company

Kodiak Sciences is a public biotech focused on retinal vascular and inflammatory diseases, with a pipeline anchored on tarcocimab and KSI-501—biopolymer conjugates designed to extend durability and target multiple disease pathways beyond standard anti-VEGF approaches. The tech stack reveals a parallel infrastructure: clinical-grade pharma tools (Medidata, Veeva, CDISC) sit alongside a sophisticated imaging and AI stack (PyTorch, TensorFlow, JAX, real-time optical subsystems, signal processing on FPGAs)—a pattern that signals active development of a proprietary imaging platform (Veti AI Foundation) to accelerate preclinical validation and mechanistic understanding.

Tech Stack 29 technologies

Core StackPython C++ PyTorch TensorFlow MATLAB AWS LC-MS HPLC PyMol JAX ONNX TensorRT Verilog SystemVerilog Xilinx AMD Intel Altera Altium Cadence Zemax FPGAs LiDAR MEMS Medidata Rave Oracle Clinical Veeva CDISC Azure

What Kodiak Sciences Is Building

◆Challenges

Accelerating program timelines
Deepening mechanistic understanding
Prototype to mass production
Complex imaging system development
Optical system validation

▲Active Projects

Veti platform ai foundation
Preclinical proof-of-concept studies
Pharmacokinetic/pharmacodynamic modeling
Animal model development
Real-time imaging and device-control stack
Wearable imaging and sensing systems electronics development
Advanced computing platform architecture for high-speed signal and ai processing
Motion-control hardware with real-time closed-loop feedback
Confocal laser scanning oct subsystems
Optical system modeling in zemax

Hiring Activity

Accelerating5 roles · 5 in 30d

Department

Engineering

Research

Seniority

Senior

Company intelligence

Find more companies like Kodiak Sciences by tech stack, pain points and active projects

Get started free

About Kodiak Sciences

Kodiak develops next-generation therapeutics for high-prevalence retinal diseases using its ABC Platform™, which combines antibody and chemistry-based approaches through molecular engineering. The company is advancing three lead candidates: tarcocimab (anti-VEGF), KSI-501 (bispecific anti-IL-6/VEGF), and KSI-101 (anti-IL-6 protein), each targeting vascular or inflammatory retinal pathology. Operations span preclinical discovery (animal models, pharmacokinetic modeling, optical imaging systems) through clinical development (Oracle Clinical, Medidata Rave). Hiring is concentrated in engineering and senior-level roles, reflecting acceleration of platform and device development work.

HeadquartersPalo Alto, California

Company Size51–200 employees

Founded2009

Hiring MarketsUnited States

Frequently Asked Questions

What is Kodiak Sciences developing?

Kodiak develops retinal therapeutics using its ABC Platform™ to merge antibody and chemistry-based therapies. Lead programs include tarcocimab (anti-VEGF), KSI-501 (bispecific anti-IL-6/VEGF), and KSI-101 (anti-IL-6 protein) for retinal vascular and inflammatory diseases.

What tech stack does Kodiak Sciences use?

Kodiak uses LC-MS and HPLC for analytical chemistry, PyTorch/TensorFlow/JAX for AI, Medidata/Veeva for clinical data, and advanced imaging hardware (Zemax, Cadence, FPGAs, LiDAR, MEMS) for real-time optical systems and device control.

How this profile is built

Kodiak Sciences's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →

This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.